On Friday, Karyopharm Therapeutics Inc (NASDAQ: KPTI) opened lower -3.54% from the last session, before settling in for the closing price of $0.80. Price fluctuations for KPTI have ranged from $0.62 to $1.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 52.21% over the past five years. Company’s average yearly earnings per share was noted 43.09% at the time writing. With a float of $115.30 million, this company’s outstanding shares have now reached $125.30 million.
Let’s look at the performance matrix of the company that is accounted for 325 employees. In terms of profitability, gross margin is 95.68%, operating margin of -84.86%, and the pretax margin is -58.73%.
Karyopharm Therapeutics Inc (KPTI) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Karyopharm Therapeutics Inc is 8.63%, while institutional ownership is 47.15%. The most recent insider transaction that took place on Dec 04 ’24, was worth 2,932. In this transaction President and CEO of this company sold 3,620 shares at a rate of $0.81, taking the stock ownership to the 1,128,312 shares. Before that another transaction happened on Nov 05 ’24, when Company’s President and CEO sold 3,675 for $0.91, making the entire transaction worth $3,346. This insider now owns 1,131,932 shares in total.
Karyopharm Therapeutics Inc (KPTI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.09% per share during the next fiscal year.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Check out the current performance indicators for Karyopharm Therapeutics Inc (KPTI). In the past quarter, the stock posted a quick ratio of 2.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.14, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Karyopharm Therapeutics Inc (NASDAQ: KPTI) saw its 5-day average volume 1.13 million, a negative change from its year-to-date volume of 1.22 million. As of the previous 9 days, the stock’s Stochastic %D was 21.39%. Additionally, its Average True Range was 0.06.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 19.60%, which indicates a significant increase from 12.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.62% in the past 14 days, which was lower than the 71.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8462, while its 200-day Moving Average is $0.9897. Nevertheless, the first resistance level for the watch stands at $0.7983 in the near term. At $0.8283, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8475. If the price goes on to break the first support level at $0.7491, it is likely to go to the next support level at $0.7299. Assuming the price breaks the second support level, the third support level stands at $0.6999.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
There are currently 125,315K shares outstanding in the company with a market cap of 93.51 million. Presently, the company’s annual sales total 146,030 K according to its annual income of -143,100 K. Last quarter, the company’s sales amounted to 38,780 K and its income totaled -32,070 K.
